Advertisement

A Nanoparticle for Tumor Targeted Delivery of Oligomers

  • Xinrong Liu
  • Yi Wang
  • Donald J. HnatowichEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 764)

Abstract

The tissue-specific delivery nanoparticle consists of an antisense oligomer, a cell-penetrating peptide, and an antitumor antibody, each biotinylated and each linked via streptavidin. Within the nanoparticle, the antibody provides specific targeted delivery and binding to the target cells, the peptide improves cell membrane transport, and the antisense oligomer, through its mRNA-binding ability, provides specific retention of the radioactivity in the target cell nucleus. The use of streptavidin as linker eliminates the need for covalent conjugation without appearing to interfere with the in vitro and in vivo properties of each component. The delivery nanoparticle is under development to improve tumor targeting with unlabeled siRNAs as well as radiolabeled antisense oligomers in a variety of tumor types. The anti-HER2 Trastuzumab (Herceptin) antibody, the tat peptide, and a radiolabeled antisense oligomer against the RIα mRNA have been used in this report as an example.

Key words

Tumor delivery streptavidin nanoparticle antisense 

Notes

Acknowledgments

This work was supported in part by the Office of Science (BER), U.S. Department of Energy (grant DE-FG02-03ER63602); the National Institutes of Health (grant R01CA94994 and R21CA129591); and congressionally directed Medical Research Programs (grant W81XWH-06-1-0649).

References

  1. 1.
    Nakamura, K., Wang, Y., Liu, X., Kitamura, N., Kubo, A., and Hnatowich, D. J. (2007) Cell culture and xenografted animal studies of radiolabeled antisense DNA/carrier nanoparticles using streptavidin as linker. J. Nucl. Med. 48, 1845–1852.PubMedCrossRefGoogle Scholar
  2. 2.
    Song, E., Zhu, P., Lee, S. K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709–717.PubMedCrossRefGoogle Scholar
  3. 3.
    Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., et al. (2004) Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 3, 379–398.PubMedCrossRefGoogle Scholar
  4. 4.
    Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang, Y., Nakamura, K., Liu, X., Kitamura, N., Kubo, A., and Hnatowich, D. J. (2007) Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture. Bioconjug. Chem. 18, 1338–1343.PubMedCrossRefGoogle Scholar
  6. 6.
    Liu, X., Wang, Y., Nakamura, K., Kubo, A., and Hnatowich, D. J. (2008) Cell studies of a three-component antisense MORF/ tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther. 15, 126–132.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu, X., Wang, Y., Nakamura, K., Kawauchi, S., Akalin, A., Cheng, D., et al. (2009) Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. J. Nucl. Med. 50, 582–590.PubMedCrossRefGoogle Scholar
  8. 8.
    Winnard, P., Chang, F., Rusckowski, M., Mardirossian, G., and Hnatowich, D. J. (1997) Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl. Med. Biol. 24, 425–432.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang, Y., Liu, G., and Hnatowich, D. J. (2006) Methods for MAG3 conjugation and 99mTc radiolabeling of biomolecules. Nat. Protoc. 1, 1477–1480.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang, Y., Liu, X., Chen, L., Cheng, D., Rusckowski, M., and Hnatowich, D. J. (2009) Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur. J. Nucl. Med. Mol. Imaging 36, 1977–1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Nuclear Medicine, Department of RadiologyUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.Department of Environmental Science and EngineeringTsinghua UniversityBeijingChina

Personalised recommendations